{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:51:19Z","timestamp":1774482679142,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dopamine receptor agonist (DA)-resistant prolactinoma presents a significant clinical challenge, highlighting the need for novel therapeutic strategies. Deguelin is a rotenoid compound derived from several plant species with unique antitumor effects. In this study we investigated the efficacy of deguelin on DA-resistant prolactinoma and elucidated its antitumor mechanisms. We showed that deguelin concentration-dependently inhibited cell viability, proliferation and prolactin secretion, and promoted apoptosis and cell cycle arrest in two prolactinoma tumor cell lines GH3 and MMQ. In CCK-8 assay, the IC\n                    <jats:sub>50<\/jats:sub>\n                    values of deguelin for GH3 and MMQ were 0.1518 and 0.2381\u2009\u00b5M, respectively. Network pharmacology analysis predicted that ornithine decarboxylase (ODC), a rate-limiting enzyme in the de novo synthesis of polyamine and responsible for converting ornithine into putrescine, was the target of deguelin. We demonstrated that deguelin directly interacted with ODC, competitively inhibiting putrescine production, and thereby reducing the levels of active Rac1. Transcriptomic analysis of deguelin-treated GH3 cells identified the PI3K\/AKT signaling pathway as a crucial mediator of the action of deguelin with the inhibition of CREB3L1 playing a central role. In GH3 xenograft nude mice, administration of deguelin (4\u2009mg\/kg, i.p., every other day for two weeks) significantly inhibited tumor growth with significant reduction in both AKT phosphorylation and CREB3L1 levels in deguelin-treated xenografts. These results suggest that deguelin can be considered a therapeutic option for treating DA-resistant prolactinoma and serve as a basis for developing novel treatment approaches.\n                  <\/jats:p>","DOI":"10.1038\/s41401-025-01686-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:38:21Z","timestamp":1762180701000},"page":"999-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K\/AKT\/CREB3L1 pathway and ornithine decarboxylase"],"prefix":"10.1038","volume":"47","author":[{"given":"Lei","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-xiao-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-yue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-yi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1686_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol. 2023;19:722\u201340.","journal-title":"Nat Rev Endocrinol"},{"key":"1686_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","volume":"12","author":"J Trouillas","year":"2020","unstructured":"Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to classify the pituitary neuroendocrine tumors (pitnet)s in 2020. Cancers. 2020;12:514.","journal-title":"Cancers"},{"key":"1686_CR3","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33:101290.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1686_CR4","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.3390\/cancers14153604","volume":"14","author":"N Fukuhara","year":"2022","unstructured":"Fukuhara N, Nishiyama M, Iwasaki Y. Update in pathogenesis, diagnosis, and therapy of prolactinoma. Cancers. 2022;14:3604.","journal-title":"Cancers"},{"key":"1686_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102883","volume":"54","author":"I Shimon","year":"2023","unstructured":"Shimon I. Prolactinomas resistant to dopamine agonists: pathophysiology and treatment. Arch Med Res. 2023;54:102883.","journal-title":"Arch Med Res"},{"key":"1686_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485\u2013534.","journal-title":"Endocr Rev"},{"key":"1686_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.wneu.2018.02.188","volume":"115","author":"X Liu","year":"2018","unstructured":"Liu X, Liu Y, Gao J, Feng M, Bao X, Deng K, et al. Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas: pilot study. World Neurosurg. 2018;115:94\u201398.","journal-title":"World Neurosurg"},{"key":"1686_CR9","doi-asserted-by":"publisher","first-page":"101056","DOI":"10.1016\/j.drup.2024.101056","volume":"73","author":"J Cheng","year":"2024","unstructured":"Cheng J, Xie W, Chen Y, Sun Y, Gong L, Wang H, et al. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug Resist Updat. 2024;73:101056.","journal-title":"Drug Resist Updat"},{"key":"1686_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/cncr.32069","volume":"125","author":"RS Varughese","year":"2019","unstructured":"Varughese RS, Lam WS, Marican AABH, Viganeshwari SH, Bhave AS, Syn NL, et al. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer. 2019;125:1789\u201398.","journal-title":"Cancer"},{"key":"1686_CR11","doi-asserted-by":"publisher","first-page":"1571452","DOI":"10.3389\/fphar.2025.1571452","volume":"16","author":"W Jiang","year":"2025","unstructured":"Jiang W, Zeng J, Guo L, Shi J, Lei Y. Deguelin\u2019s anticancer bioactivity: challenges and opportunities in medicinal chemistry. Front Pharmacol. 2025;16:1571452.","journal-title":"Front Pharmacol"},{"key":"1686_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3892\/mco.2012.36","volume":"1","author":"Y Wang","year":"2013","unstructured":"Wang Y, Ma W, Zheng W. Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol Clin Oncol. 2013;1:215\u20139.","journal-title":"Mol Clin Oncol"},{"key":"1686_CR13","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1002\/ijc.25949","volume":"129","author":"V Thamilselvan","year":"2011","unstructured":"Thamilselvan V, Menon M, Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 \u03b2\/\u03b2-catenin pathway. Int J Cancer. 2011;129:2916\u201327.","journal-title":"Int J Cancer"},{"key":"1686_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/tox.22214","volume":"32","author":"Y-C Hsu","year":"2017","unstructured":"Hsu YC, Chiang JH, Yu CS, Hsia TC, Wu RSC, Lien JC, et al. Antitumor effects of deguelin on h460 human lung cancer cells in vitro and in vivo: roles of apoptotic cell death and h460 tumor xenografts model. Environ Toxicol. 2017;32:84\u201398.","journal-title":"Environ Toxicol."},{"key":"1686_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1124\/jpet.107.132720","volume":"324","author":"JH Kim","year":"2008","unstructured":"Kim JH, Kim JH, Yu YS, Park KH, Kang HJ, Lee HY, et al. Antiangiogenic effect of deguelin on choroidal neovascularization. J Pharmacol Exp Ther. 2008;324:643\u20137.","journal-title":"J Pharmacol Exp Ther."},{"key":"1686_CR16","doi-asserted-by":"publisher","first-page":"16588","DOI":"10.18632\/oncotarget.3752","volume":"6","author":"MP Nguyen","year":"2015","unstructured":"Nguyen MP, Lee D, Lee SH, Lee HE, Lee HY, Lee YM. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion. Oncotarget. 2015;6:16588\u2013600.","journal-title":"Oncotarget."},{"key":"1686_CR17","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1038\/onc.2012.413","volume":"32","author":"SR Boreddy","year":"2013","unstructured":"Boreddy SR, Srivastava SK. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene. 2013;32:3980\u201391.","journal-title":"Oncogene"},{"key":"1686_CR18","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357\u2013W364.","journal-title":"Nucleic Acids Res"},{"key":"1686_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nbt1284","volume":"25","author":"MJ Keiser","year":"2007","unstructured":"Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25:197\u2013206.","journal-title":"Nat Biotechnol"},{"key":"1686_CR20","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022;50:W159\u2013W164.","journal-title":"Nucleic Acids Res."},{"key":"1686_CR21","doi-asserted-by":"publisher","first-page":"14529","DOI":"10.1074\/jbc.R500031200","volume":"281","author":"AE Pegg","year":"2006","unstructured":"Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem. 2006;281:14529\u201332.","journal-title":"J Biol Chem."},{"key":"1686_CR22","first-page":"3429","volume":"57","author":"C Gerhauser","year":"1997","unstructured":"Gerhauser C, Lee SK, Kosmeder JW, Moriarty RM, Hamel E, Mehta RG, et al. Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res. 1997;57:3429\u201335.","journal-title":"Cancer Res"},{"key":"1686_CR23","doi-asserted-by":"publisher","first-page":"13230","DOI":"10.1021\/bi0155908","volume":"40","author":"DP Myers","year":"2001","unstructured":"Myers DP, Jackson LK, Ipe VG, Murphy GE, Phillips MA. Long-range interactions in the dimer interface of ornithine decarboxylase are important for enzyme function. Biochemistry. 2001;40:13230\u20136.","journal-title":"Biochemistry"},{"key":"1686_CR24","doi-asserted-by":"publisher","first-page":"12990","DOI":"10.1021\/bi048933l","volume":"43","author":"LK Jackson","year":"2004","unstructured":"Jackson LK, Baldwin J, Akella R, Goldsmith EJ, Phillips MA. Multiple active site conformations revealed by distant site mutation in ornithine decarboxylase. Biochemistry. 2004;43:12990\u20139.","journal-title":"Biochemistry"},{"key":"1686_CR25","doi-asserted-by":"publisher","first-page":"13039","DOI":"10.1074\/jbc.M208741200","volume":"278","author":"RM Ray","year":"2003","unstructured":"Ray RM, McCormack SA, Covington C, Viar MJ, Zheng Y, Johnson LR. The requirement for polyamines for intestinal epithelial cell migration is mediated through Rac1*. J Biol Chem. 2003;278:13039\u201346.","journal-title":"J Biol Chem"},{"key":"1686_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1042\/bj3150775","volume":"315","author":"GM Bokoch","year":"1996","unstructured":"Bokoch GM, Vlahos CJ, Wang Y, Knaus UG, Traynor-Kaplan AE. Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Biochem J. 1996;315:775.","journal-title":"Biochem J"},{"key":"1686_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.molcel.2012.05.007","volume":"47","author":"HW Yang","year":"2012","unstructured":"Yang HW, Shin MG, Lee S, Kim JR, Park WS, Cho KH, et al. Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell. 2012;47:281\u201390.","journal-title":"Mol Cell."},{"key":"1686_CR28","first-page":"35","volume":"50","author":"KE Mayo","year":"1995","unstructured":"Mayo KE, Godfrey PA, Suhr ST, Kulik DJ, Rahal JO. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:35\u201373.","journal-title":"Recent Prog Horm Res"},{"key":"1686_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0092-8674(88)90038-4","volume":"55","author":"HA Ingraham","year":"1988","unstructured":"Ingraham HA, Chen RP, Mangalam HJ, Elsholtz HP, Flynn SE, Lin CR, et al. A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype. Cell. 1988;55:519\u201329.","journal-title":"Cell"},{"key":"1686_CR30","doi-asserted-by":"publisher","first-page":"105935","DOI":"10.1016\/j.phrs.2021.105935","volume":"174","author":"ZY Lin","year":"2021","unstructured":"Lin ZY, Yun QZ, Wu L, Zhang TW, Yao TZ. Pharmacological basis and new insights of deguelin concerning its anticancer effects. Pharmacol Res. 2021;174:105935.","journal-title":"Pharmacol Res"},{"key":"1686_CR31","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/jnci\/djm007","volume":"99","author":"SH Oh","year":"2007","unstructured":"Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. JNCI J Natl Cancer Inst. 2007;99:949\u201361.","journal-title":"JNCI J Natl Cancer Inst."},{"key":"1686_CR32","doi-asserted-by":"crossref","unstructured":"Lokhande KB, Nagar S, Swamy KV. Molecular interaction studies of deguelin and its derivatives with cyclin D1 and cyclin E in cancer cell signaling pathway: the computational approach. Sci Rep. 2019;9:1778.","DOI":"10.1038\/s41598-018-38332-6"},{"key":"1686_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ebiom.2017.10.030","volume":"26","author":"X Yu","year":"2017","unstructured":"Yu X, Liang Q, Liu W, Zhou L, Li W, Liu H. Deguelin, an aurora B kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma. EBioMedicine. 2017;26:100\u201311.","journal-title":"EBioMedicine"},{"key":"1686_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01545-9","volume":"20","author":"J Li","year":"2020","unstructured":"Li J, Meng Y, Wu X, Sun Y. Polyamines and related signaling pathways in cancer. Cancer Cell Int. 2020;20:539.","journal-title":"Cancer Cell Int"},{"key":"1686_CR35","doi-asserted-by":"crossref","unstructured":"Kaprio T, Rasila T, Hagstr\u00f6m J, Mustonen H, Lankila P, Haglund C, et al. Ornithine decarboxylase antizyme inhibitor 2 (azin2) is a signature of secretory phenotype and independent predictor of adverse prognosis in colorectal cancer. PLoS One. 2019;14:e0211564.","DOI":"10.1371\/journal.pone.0211564"},{"key":"1686_CR36","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1016\/j.ajpath.2016.08.021","volume":"186","author":"A Shukla-Dave","year":"2016","unstructured":"Shukla-Dave A, Castillo-Martin M, Chen M, Lobo J, Gladoun N, Collazo-Lorduy A, et al. Ornithine decarboxylase is sufficient for prostate tumorigenesis via androgen receptor signaling. Am J Pathol. 2016;186:3131\u201345.","journal-title":"Am J Pathol"},{"key":"1686_CR37","doi-asserted-by":"crossref","unstructured":"Kim H, Schultz C, Buras A, Buras A, Friedman E, Fedorko A, et al. Ornithine decarboxylase as a therapeutic target for endometrial cancer. PLoS One. 2017;12:e0189044.","DOI":"10.1371\/journal.pone.0189044"},{"key":"1686_CR38","doi-asserted-by":"crossref","unstructured":"Weiss R, Calhoun K, Ahmed A, Stanley D. Ornithine decarboxylase activity in tumor and normal tissue of head and neck cancer patients. Laryngoscope. 1992;102:855-7.","DOI":"10.1288\/00005537-199208000-00003"},{"key":"1686_CR39","first-page":"1448","volume":"51","author":"J Okuzumi","year":"1991","unstructured":"Okuzumi J, Yamane T, Kitao Y, Tokiwa K, Yamaguchi T, Fujita Y, et al. Increased mucosal ornithine decarboxylase activity in human gastric cancer. Cancer Res. 1991;51:1448\u201351.","journal-title":"Cancer Res"},{"key":"1686_CR40","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.7314\/APJCP.2012.13.5.2425","volume":"13","author":"S Luqman","year":"2012","unstructured":"Luqman S. Ornithine decarboxylase: a promising and exploratory candidate target for natural products in cancer chemoprevention. Asian Pac J Cancer Prev Apjcp. 2012;13:2425\u20137.","journal-title":"Asian Pac J Cancer Prev Apjcp"},{"key":"1686_CR41","doi-asserted-by":"crossref","unstructured":"Nowotarski S, Woster P, Casero R. Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med. 2013;15:2425\u20137.","DOI":"10.1017\/erm.2013.3"},{"key":"1686_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/B978-0-12-387025-4.00002-9","volume":"54","author":"E Paz","year":"2011","unstructured":"Paz E, Garc\u00eda-Huidobro J, Ignatenko N. Polyamines in cancer. Adv Clin Chem. 2011;54:45\u201370.","journal-title":"Adv Clin Chem"},{"key":"1686_CR43","first-page":"95","volume":"30","author":"K Soda","year":"2011","unstructured":"Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res Cr. 2011;30:95\u201395.","journal-title":"J Exp Clin Cancer Res Cr"},{"key":"1686_CR44","doi-asserted-by":"crossref","unstructured":"Lian J, Liang Y, Zhang H, Lan M, Ye Z, Lin B, et al. The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. Front Immunol. 2022;13:912279.","DOI":"10.3389\/fimmu.2022.912279"},{"key":"1686_CR45","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1111\/febs.17052","volume":"291","author":"A Saito","year":"2024","unstructured":"Saito A, Omura I, Imaizumi K. CREB3L1\/oasis: cell cycle regulator and tumor suppressor. FEBS J. 2024;291:4853\u201366.","journal-title":"FEBS J"},{"key":"1686_CR46","doi-asserted-by":"crossref","unstructured":"Ke M, Pa G, St S, Dj K, Jo R. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:35\u201373.","DOI":"10.1016\/B978-0-12-571150-0.50007-X"},{"key":"1686_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/346583a0","volume":"346","author":"RP Chen","year":"1990","unstructured":"Chen RP, Ingraham HA, Treacy MN, Albert VR, Wilson L, Rosenfeld MG. Autoregulation of pit-1 gene expression mediated by two cis-active promoter elements. Nature. 1990;346:583\u20136.","journal-title":"Nature"},{"key":"1686_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1940-6207.CAPR-08-0184","volume":"1","author":"W-Y Kim","year":"2008","unstructured":"Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res Phila Pa. 2008;1:577\u201387.","journal-title":"Cancer Prev Res Phila Pa."},{"key":"1686_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s002800000187","volume":"47","author":"GO Udeani","year":"2001","unstructured":"Udeani GO, Zhao GM, Shin YG, Kosmeder JW, Beecher CW, Kinghorn AD, et al. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer Chemother Pharmacol. 2001;47:263\u20138.","journal-title":"Cancer Chemother Pharmacol"}],"updated-by":[{"DOI":"10.1038\/s41401-026-01769-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000}}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01686-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:02:21Z","timestamp":1774479741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01686-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01686-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41401-026-01769-x","URL":"https:\/\/doi.org\/10.1038\/s41401-026-01769-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}